First‐in‐man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M1‐receptor partial agonist for the treatment of dementias

• Published in: British journal of clinical pharmacology Vol. 87; no. 7; pp. 2945 - 2955
• Main Authors: Bakker, Charlotte, Tasker, Tim, Liptrot, Jan, Hart, Ellen P., Klaassen, Erica S., Prins, Samantha, Doef, Thalia F., Brown, Giles A., Brown, Alastair, Congreve, Miles, Weir, Malcolm, Marshall, Fiona H., Cross, David M., Groeneveld, Geert Jan, Nathan, Pradeep J.
• Format: Journal Article
• Language: English
• Published: Hoboken John Wiley and Sons Inc 01.07.2021
• Subjects: Alzheimer's disease; healthy subjects; muscarinic; Original; pharmacokinetics; safety

Aims HTL0018318 is a selective M1 receptor partial agonist currently under development for the symptomatic treatment of cognitive and behavioural symptoms in Alzheimer's disease and other dementias. We investigated safety, tolerability, pharmacokinetics and exploratory pharmacodynamics (PD) of...